Natera has begun the subject enrolment in the randomised Phase III SAGITTARIUS clinical trial designed to assess the ...

根据美国证券交易委员会的一份文件显示，Natera, Inc.（纳斯达克股票代码：NTRA）的执行董事长Matthew Rabinowitz最近出售了大量公司股票。该公司股票今年以来已上涨超过165%，目前在52周高点附近交易，价格为166.55美元。根据 InvestingPro ...

Currently trading with a volume of 643,596, the NTRA's price is up by 3.63%, now at $172.49. RSI readings suggest the stock ...

Natera (NTRA) announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...

JPMorgan analyst Rachel Vatnsdal raised the firm’s price target on Natera (NTRA) to $200 from $160 and keeps an Overweight rating on the ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...

Natera, Inc.（纳斯达克股票代码：NTRA）的董事Chapman Rowan ...

Natera, Inc. (NASDAQ:NTRA – Get Free Report) has earned an average rating of “Buy” from the seventeen ratings firms that are ...

We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a ...

Cross-ancestry polygenic risk score now offered with the Empower™ hereditary cancer test AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic ...

Updates shares, adds Guardant comment. Guardant Health (NASDAQ:GH) rose 8.4% at least partly after a North California jury ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole genome analysis and polygenic risk modeling company, today announced the launch ...